Evaluating the effects of probiotics in pediatrics with recurrent abdominal pain
Authors:
- Parisa RahmaniPRParisa Rahmani
- Azin Ghouran-OrimiAGAzin Ghouran-Orimi
- Farzaneh MotamedFMFarzaneh Motamed
- Alireza MoradzadehAMAlireza Moradzadeh
Open Access
- 15 December 2020
- journal article
- research article
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 63 (12) , 485-490
Abstract
Background: Recurrent abdominal pain (RAP) is one of the frequent complaints in general practice, particularly in pediatrics and is among the common cause of referral to gastroenterology clinics.Purpose: This study is designed to investigate the effects of probiotics for the treatment of RAP and desired therapeutic outcomes.Methods: One hundred twenty-five children with the diagnosis of RAP according to Rome III criteria for irritable bowel syndrome (IBS), functional abdominal pain (FAP), functional dyspepsia (FD), and abdominal migraine (AM), were enrolled in this double-blind randomized controlled trial.Results: Sixty-five subjects received probiotics, and others received placebo treatment for 4 weeks. Lactobacillus reuteri was therapeutically effective in 32 patients compared to 8 patients, responding to the placebo treatment. Compared to baseline, all pain-related variables showed a significant reduction for the IBS and FD at the end of the 4th week. However, it did not respond well in FAP and AM groups. Pain-related outcomes such as, frequency of the pain, severity, and duration of the pain were decreased following the probiotic treatment. No therapeutic response was seen in AM group after the administration of probiotics. L. reuteri significantly led to pain relief in the overall population, and also in FAP, FD, and IBS subgroups.Conclusion: L. reuteri probiotics are likely to lead to RAP relief and can be recommended for the treatment of functional gastrointestinal disorders.Keywords
This publication has 18 references indexed in Scilit:
- Lactobacillus reuteri in children with functional abdominal pain (FAP)Journal of Paediatrics and Child Health, 2014
- Lactobacillus reuteristrains reduce incidence and severity of experimental necrotizing enterocolitis via modulation of TLR4 and NF-κB signaling in the intestineAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2012
- Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhoodAlimentary Pharmacology & Therapeutics, 2011
- Lactobacillus rhamnosus GGreduces frequency and severity of abdominal pain compared with placebo in children with irritable bowel syndromeBMJ Evidence-Based Medicine, 2011
- A Randomized Controlled Trial of Lactobacillus GG in Children With Functional Abdominal PainPediatrics, 2010
- Lactobacillus reuteriDSM 17938 in Infantile Colic: A Randomized, Double-Blind, Placebo-Controlled TrialPediatrics, 2010
- Lactobacillus reuteri ingestion and IKCa channel blockade have similar effects on rat colon motility and myenteric neuronesNeurogastroenterology & Motility, 2009
- The Effects of Probiotics on Feeding Tolerance, Bowel Habits, and Gastrointestinal Motility in Preterm NewbornsThe Journal of Pediatrics, 2008
- A randomized double‐blind placebo‐controlled trial of Lactobacillus GG for abdominal pain disorders in childrenAlimentary Pharmacology & Therapeutics, 2006
- Colonization and Immunomodulation by Lactobacillus reuteri ATCC 55730 in the Human Gastrointestinal TractApplied and Environmental Microbiology, 2004